Latest PhIII results multiply Novartis/Incyte's Jakafi sales potential
This article was originally published in Scrip
Executive Summary
Novartis and Incyte have added another string to Jakafi/Jakavi's bow as the drug has hit its primary endpoint in a pivotal Phase III trial in patients with polycythemia vera, a rare blood cancer. The new indication could add almost 50% to the drug's US sales, and Novartis confirmed that Jakafi now has the potential to be a blockbuster.